Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development	$ 41,827	$ 41,414
In process research and development	30	2,805
General and administrative	11,346	10,748
Total operating expenses	53,203	54,967
Loss from operations	(53,203)	(54,967)
Other income (expense), net
Interest income	193	1,598
Interest expense	(4,780)	(707)
Other income	149	2
Total other income (expense), net	(4,438)	893
Net loss	(57,641)	(54,074)
Other comprehensive loss:
Foreign currency translation, net of tax	(372)	(87)
Unrealized loss on marketable securities, net of tax	(69)	(676)
Other comprehensive loss	(441)	(763)
Comprehensive loss	$ (58,082)	$ (54,837)
Net loss per share, basic (in dollars per share)	$ (0.78)	$ (0.87)
Net loss per share, diluted (in dollars per share)	$ (0.78)	$ (0.87)
Weighted average common shares outstanding, basic (in shares)	74,093,526	61,890,323
Weighted average common shares outstanding, diluted (in shares)	74,093,526	61,890,323